Lucy T Xu1, Pauline F Funchain2, James F Bena3, Manshi Li3, Ahmad Tarhini2,4, Eren Berber5, Arun D Singh1. 1. Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 2. Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 3. Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 4. Case Comprehensive Cancer Center, Cleveland, Ohio, USA. 5. Center for Endocrine Surgery, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Abstract
OBJECTIVE: To describe treatment trends and outcomes of liver metastasis from uveal melanoma. METHODS: Retrospective case series of 73 patients with uveal melanoma liver metastasis. Patients were treated first-line with systemic therapy (not including checkpoint inhibitors), checkpoint inhibitors, local therapy or no treatment. Time to metastasis, detection method, and survival data were collected. Time periods were divided between 2004-2011 and 2012-2016. Cox proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS). RESULTS: Median PFS and OS for the entire cohort was 4 months (95% CI 3-5) and 15 months (95% CI 11-18), respectively. There was no statistically significant difference in PFS and OS across the two time periods. Patients who received no treatment had the shortest OS (median 4.9 months), whereas those treated with local therapy had the longest PFS (median 4.6 months) and OS (median 18.7 months). Having liver metastasis diagnosed by symptoms was associated with a greater risk of mortality (p < 0.001). CONCLUSION: Patients who received first-line local treatment had the longest PFS and OS, while patients who received no treatment had the shortest OS. Survival outcomes did not improve for patients including those receiving check point inhibitors.
OBJECTIVE: To describe treatment trends and outcomes of liver metastasis from uveal melanoma. METHODS: Retrospective case series of 73 patients with uveal melanoma liver metastasis. Patients were treated first-line with systemic therapy (not including checkpoint inhibitors), checkpoint inhibitors, local therapy or no treatment. Time to metastasis, detection method, and survival data were collected. Time periods were divided between 2004-2011 and 2012-2016. Cox proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS). RESULTS: Median PFS and OS for the entire cohort was 4 months (95% CI 3-5) and 15 months (95% CI 11-18), respectively. There was no statistically significant difference in PFS and OS across the two time periods. Patients who received no treatment had the shortest OS (median 4.9 months), whereas those treated with local therapy had the longest PFS (median 4.6 months) and OS (median 18.7 months). Having liver metastasis diagnosed by symptoms was associated with a greater risk of mortality (p < 0.001). CONCLUSION: Patients who received first-line local treatment had the longest PFS and OS, while patients who received no treatment had the shortest OS. Survival outcomes did not improve for patients including those receiving check point inhibitors.
Authors: A Farolfi; L Ridolfi; M Guidoboni; C Milandri; F Calzolari; E Scarpi; D Amadori; R Ridolfi Journal: J Chemother Date: 2011-10 Impact factor: 1.714
Authors: Marie Diener-West; Sandra M Reynolds; Donna J Agugliaro; Robert Caldwell; Kristi Cumming; John D Earle; Barbara S Hawkins; James A Hayman; Ishmael Jaiyesimi; Lee M Jampol; John M Kirkwood; Wui-Jin Koh; Dennis M Robertson; John M Shaw; Bradley R Straatsma; Jonni Thoma Journal: Arch Ophthalmol Date: 2005-12
Authors: Petra Rietschel; Katherine S Panageas; Christine Hanlon; Ami Patel; David H Abramson; Paul B Chapman Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Nathalie A Kolandjian; Caimiao Wei; Sapna P Patel; Jessica L Richard; Tina Dett; Nicholas E Papadopoulos; Agop Y Bedikian Journal: Am J Clin Oncol Date: 2013-10 Impact factor: 2.339
Authors: Francesc Pons; Maria Plana; Josep Maria Caminal; Joan Pera; Isabel Fernandes; Javier Perez; Xavier Garcia-Del-Muro; Joaquim Marcoval; Rosa Penin; Angels Fabra; Josep Maria Piulats Journal: Melanoma Res Date: 2011-06 Impact factor: 3.599
Authors: P Mariani; S Piperno-Neumann; V Servois; M G Berry; T Dorval; C Plancher; J Couturier; C Levy-Gabriel; L Lumbroso-Le Rouic; L Desjardins; R J Salmon Journal: Eur J Surg Oncol Date: 2009-03-28 Impact factor: 4.424
Authors: Beatriz Quiles; Jorge Mataix; José Luis Guinot; Isabel Wang; Victor De Los Dolores; Marina Peña; Alonso La Rosa; Maribel Tortajada; Miguel Santos; Leoncio Arribas Journal: Ocul Oncol Pathol Date: 2021-05-05
Authors: T M L Tong; M K van der Kooij; F M Speetjens; A R van Erkel; R W van der Meer; J Lutjeboer; E L van Persijn van Meerten; C H Martini; R W M Zoethout; F G J Tijl; C U Blank; M C Burgmans; E Kapiteijn Journal: Trials Date: 2022-02-13 Impact factor: 2.279
Authors: T M L Tong; M Samim; E Kapiteijn; T S Meijer; F M Speetjens; R Brüning; T H Schroeder; S El-Sanosy; H Maschke; F K Wacker; A Vogel; C L A Dewald; J J Goeman; M C Burgmans Journal: Cardiovasc Intervent Radiol Date: 2022-08-03 Impact factor: 2.797